Neumora Therapeutics
Updated: December 08, 2025
Lori Lyons-Williams, chief operating officer
Country: USA | Funding: $614.6M (+)
Founded: 2019
Website: https://neumoratx.com/
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
Founded: 2019
Website: https://neumoratx.com/
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
